Effectiveness of the human placenta hydrolyzate in the treatment of menopausal symptoms in women in the menopausal transition


Cite item

Abstract

Contraindications to hormone therapy in peri - and postmenopausal periods, as well as giving up hormones determine the relevance of the search for alternative methods of relief of menopausal disorders. Thus we conducted a comparative study of the effectiveness of the hydrolyzate of human placenta and phytoestrogens in women of peri- and postmenopausal period with the presence of symptoms caused by estrogen deficiency. Evaluation of initial severity of menopausal disorders and the effectiveness of therapy was carried out by the Cupperman index. The study had a positive effect, in response to a human placenta hydrolyzate therapy and using phytoestrogens. But the decline of Cupperman index in the group of women treated with hydrolyzate of human placenta was significantly greater, and continued to grow in the period after treatment , whereas the decrease in the Cupperman index while taking phytoestrogens was observed during the first two months of receiving stabilizing for subsequent treatment. Application of human placenta hydrolyzate had a positive effect on blood pressure in patients with hypertension and improved blood lipid. Thus, the use of the hydrolyzate of human placenta can serve as an alternative hormonal therapy in women of peri - and post-menopausal age.

About the authors

I V Kuznetsova

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

A V Gilels

Медицинская корпорация RHANA, Москва

Yu B Uspenskaya

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

N S Suleymanova

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

References

  1. Sturdee D.W et al. Updated I.M.S recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011; 14: 302–20.
  2. Usui T. Pharmaceutical prospects of phytoestrogens. Endocr J 2006; 53 (1): 7–20.
  3. Kupperman H.S, Wetchler B.B, Blat M.H.G. Contemporary therapy of the menopausal syndrome. JAMA 1959; 171: 1627–37.
  4. Alexander J.L, Dennerstein L, Woody N.F et al. Arthalgias, bodily aches and pains and somatic complaints in midlife women: etiology, pathophysiology and differential diagnosis. Expert rev Neurother 2007; 7 (Suppl. 11): S15–26.
  5. Freeman E.X, Sammel M.D, Lin H et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007; 110: 230–40.
  6. Chedraui P, Aguirre W, Hidalgo L, Fayad L. Assessing menopausal symptoms among healthy middle aged women with the Menopause rating Scale. Maturitas 2007; 57: 271–8.
  7. Freedman R.R. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005; 23: 117–25.
  8. Moe K.E. Hot flashes and sleep in women. Sleep Med Rev 2004; 8: 487–9.
  9. Pérez J.A.M, Garcia F.C, Palacios S, Pérez M. Epidemiology of risk factors and symptoms associated with menopause in Spanish women. Maturitas 2009; 62: 30–6.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).